• About
  • Blog
  1. Home
  2. Blog
  3. Companies
  4. ABT

Abbott Laboratories(ABT)

New York Stock Exchange
Sector: Healthcare | Industry: Medical - Devices
Abbott Laboratories logo

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Latest News & Analysis

Modern medical device prototypes in a sleek laboratory with hints of innovation and growth
Jul 28, 2025

Abbott Laboratories Q2 2025 Analysis: Medical Device Growth Amid Diagnostics Challenges

Explore Abbott Laboratories' Q2 2025 performance, focusing on medical device innovation, diagnostics segment headwinds, dividend sustainability, and strategic growth drivers.

Read more →
Medical device and diagnostic equipment on clean lab bench with soft purple background
Jul 28, 2025

Abbott Laboratories Q2 2025 Earnings: Medical Devices Drive Growth Amid Diagnostics Challenges

Abbott Laboratories reports strong Q2 2025 sales growth led by Medical Devices, while Diagnostics face headwinds prompting a cautious full-year guidance revision.

Read more →
Wind turbines and solar panels in a wide landscape beneath a clear sky with purple tones
Jul 18, 2025

Abbott Laboratories (ABT) Surges on Robust Earnings and Strategic Financial Strength

Abbott Laboratories stock rises +3.53% post strong earnings beat; deep dive into financials, cash flow, and strategic positioning for investors.

Read more →
Glucose monitor and cardiac device on reflective desk with blurred medical equipment in soft purple light
Jul 14, 2025

Abbott Laboratories Q2 Analysis: Medical Device Growth Drives Strong Financials | Monexa AI

Abbott Laboratories' Q2 growth is fueled by its Medical Devices segment, with strong CGM and cardiac device sales underpinning robust financial performance.

Read more →
Modern laptop computer on a sleek desk with abstract marketing icons and graphs in a purple-themed setting
Jul 11, 2025

Abbott Laboratories (ABT) Latest Corporate Update and Financial Analysis

Explore Abbott Laboratories' recent developments, financial performance, and strategic positioning amid evolving healthcare market dynamics.

Read more →
Modern glucose monitoring device on clean laboratory surface with blurred equipment in the background
Jul 10, 2025

Abbott Laboratories (ABT) Growth Drivers and Financial Strength Fuel Investor Confidence

Abbott Laboratories' innovation in medical devices and FreeStyle Libre platform, combined with strong financials, drive sustainable growth and shareholder value.

Read more →
Glucose monitor device on a sleek medical counter in a bright, softly lit clinical space
Jul 2, 2025

Abbott Laboratories (ABT) Latest Developments: FreeStyle Libre Growth, Innovation, and Financial Strength

Explore Abbott Laboratories' recent growth driven by FreeStyle Libre, medical device innovation, and robust financial performance, shaping its market leadership.

Read more →
Abstract visual representing Abbott Laboratories' leadership in medical device innovation, showcasing advancements in cardiovascular care (Tendyne) and diabetes management (FreeStyle Libre) against a clean, professional background, symbolizing strong financial growth and healthcare technology.
Jun 30, 2025

Abbott Laboratories (ABT) Latest Innovations and Financial Performance Analysis

Abbott Laboratories advances with FDA-approved Tendyne valve and FreeStyle Libre growth, supported by strong financials and strategic R&D investment.

Read more →
Medical devices and wearable health sensor in a modern lab with digital monitors and a purple background
Jun 23, 2025

Abbott Laboratories (ABT): Innovation Fuels Q1 2025 Success and Outlook

Abbott Laboratories' Q1 2025 results reveal robust growth, driven by groundbreaking innovations in cardiac care, diabetes management, and diagnostics.

Read more →
Medical diagnostic device sits on a modern lab countertop amid advanced healthcare equipment in a purple-tinted setting
Jun 22, 2025

Abbott Laboratories (ABT): Profitability Surge & Strategic Innovation in 2025

Abbott Laboratories' 2024 financial results reveal a strategic pivot towards enhanced profitability, marked by a significant net income surge.

Read more →
Healthcare laboratory equipment on a sleek countertop with digital monitors and a soft purple background
Jun 16, 2025

Abbott Laboratories (ABT): Financial Surge, Strategic Innovation & Dividends

Abbott Laboratories showcases robust financial health and strategic innovation, with a 134.27% surge in net income and continued dividend leadership.

Read more →
Medical device on modern countertop with soft purple hues and blurred clinical equipment in the background
Jun 12, 2025

Abbott Laboratories' Strategic Advances: FDA Approvals & Dividend Strength

Abbott Laboratories' recent FDA approval of the Tendyne TMVR system and advancements in Libre CGM technology are reshaping its market position and financial trajectory.

Read more →
Abbott Laboratories (ABT): Net Income Surge and Strategic Wins
Jun 5, 2025

Abbott Laboratories (ABT): Net Income Surge and Strategic Wins

Abbott Laboratories sees a surge in net income, driven by strategic wins in cardiac devices and diabetes care, signaling robust operational performance.

Read more →
Abbott (ABT) stock analysis: Volt PFA approval, TriClip trial success, dividend aristocrat status, and Q1 2025 earnings outlook for investors.
Apr 2, 2025

Abbott (ABT): Volt PFA Approval, TriClip Success, and Market Outlook

Abbott Laboratories (ABT) navigates market volatility with Volt PFA approval, TriClip success, and a consistent dividend history, making it a stable investment.

Read more →
Abbott (ABT) stock surges following Volt™ PFA system CE Mark and FDA IDE approval for Coronary IVL system; dividend yield analysis, AI integration, and future investment outlook.
Mar 27, 2025

Abbott (ABT): PFA Approval, Coronary IVL System, and Market Outlook

Abbott Laboratories (ABT) gains momentum with CE Mark approval for Volt™ PFA and FDA IDE nod for Coronary IVL, bolstering its cardiovascular portfolio.

Read more →
Abbott Laboratories (ABT) analysis: FDA approval for coronary IVL system, market impact, AI investments, and future growth prospects.
Mar 25, 2025

Abbott (ABT): FDA Approval, Market Impact, and Future Growth

Analysis of Abbott Laboratories (ABT): FDA approval for Coronary IVL System, AI initiatives, dividend growth, and strategic focus on diabetes care and weight-loss.

Read more →
Abbott Laboratories: IVL therapy, weight loss solutions, and AI-driven advancements fueling growth in the healthcare sector. Stay informed about Abbott's strategic moves.
Mar 24, 2025

Abbott Laboratories: Coronary IVL, Weight Loss, and AI Driving Growth

Abbott Laboratories is strategically positioned for growth through medical devices, expansion into weight-loss, and AI integration. Dividend payouts and financial stability enhance its appeal.

Read more →
Abbott Laboratories: Growth drivers, dividend reliability, and market outlook for 2025. Learn about ABT's FreeStyle Libre, weight-loss treatments, and financial performance.
Mar 17, 2025

Abbott (ABT): Growth, Dividends, and Market Outlook 2025

Abbott Laboratories (ABT) navigates market dynamics with strategic expansions, FreeStyle Libre advancements, and dividend reliability. A detailed analysis for investors.

Read more →
Abbott Laboratories: Analysis of earnings, dividends, growth potential, and competitive landscape.
Mar 10, 2025

Abbott Laboratories (ABT): Earnings, Dividends, and Growth Analysis

A deep dive into Abbott Laboratories' recent performance, dividend aristocrat status, and growth prospects. Discover how strategic initiatives and market dynamics shape ABT's future.

Read more →
ABT Stock Analysis: Intraday performance, financial metrics, and future outlook for Abbott Laboratories. Data-driven insights for investors.
Mar 5, 2025

Abbott Laboratories: Intraday Market Update - March 5, 2025

Intraday update on Abbott Laboratories (ABT) with key financial metrics, dividend news, strategic moves, and market trends from credible sources.

Read more →
Abbott Laboratories stock analysis: Growth drivers, market trends, and 2025 outlook. Is ABT a buy?
Feb 28, 2025

Abbott Laboratories: Analyzing Growth Drivers and Future Outlook

Abbott Laboratories (ABT) navigates 2025 with strong performance, driven by FreeStyle Libre and molecular diagnostics, despite FX headwinds. Dividend Aristocrat status enhances investor appeal.

Read more →
Abbott (ABT) Stock Analysis: Dividend King, Diabetes Care Leadership, and Molecular Diagnostics Growth in 2025. Investment insights and financial outlook.
Feb 27, 2025

Abbott (ABT) in 2025: Dividend King, Diabetes Care Leader

Abbott Laboratories (ABT) shows strong 2025 performance driven by dividends, diabetes care, and diagnostics growth, despite FX risks. A detailed analysis follows.

Read more →
Abbott Laboratories (ABT) stock analysis: Growth drivers, diabetes care, molecular diagnostics, and dividend performance.
Feb 26, 2025

Abbott Laboratories (ABT): Growth, Dividends, and Market Leadership

Comprehensive analysis of Abbott Laboratories (ABT): exploring diabetes care innovations, molecular diagnostics growth, dividend consistency, and future outlook.

Read more →
Abbott Laboratories: Growth in Diabetes Care and Molecular Diagnostics - Stock Analysis
Feb 25, 2025

Abbott Laboratories (ABT): Navigating Growth in Diabetes Care & Diagnostics

**Abbott Laboratories (ABT) demonstrates resilience and growth potential.** Driven by FreeStyle Libre and expansion in molecular diagnostics, the company maintains a steady climb.

Read more →
Abbott Laboratories: Dividend Stability, Diabetes Care Growth, and Molecular Diagnostics Opportunities in 2025
Feb 24, 2025

Abbott Laboratories: Growth Drivers, Market Trends, and Future Outlook

Abbott Laboratories navigates a dynamic healthcare landscape with consistent dividends, FreeStyle Libre growth, and molecular diagnostics opportunities. A comprehensive analysis of ABT's market position.

Read more →
Abbott's Steady Course: Dividends, Diabetes Care Growth, and Diagnostics Expansion
Feb 21, 2025

Abbott Laboratories: Dividends, Diabetes Care & Market Trends

Abbott continues to deliver consistent dividends, robust diabetes care growth, and expanding diagnostics in a competitive healthcare landscape.

Read more →
Abbott Laboratories (ABT) stock analysis: Market performance, growth drivers, and investment opportunities in diabetes care and molecular diagnostics.
Feb 21, 2025

Abbott Laboratories: Navigating Growth in Diabetes Care

Abbott Laboratories demonstrates resilience amid market volatility, driven by growth in diabetes care and strategic market expansion. ABT stock increases +0.79%.

Read more →
Futuristic medical lab with robotic arm analyzing a sample, representing advancements in healthcare diagnostics.
Feb 18, 2025

Abbott Laboratories: Navigating Growth in Diagnostics, Diabetes Care, and Dividends

A comprehensive data-driven analysis of Abbott’s Q4 performance, R&D investments, and market trends shaping its future.

Read more →

Professional-grade financial analysis tools for informed investment decisions.

Product

  • Features
  • Pricing

Resources

  • Blog
  • Knowledge Base
  • Community
  • Market Data

Company

  • About
  • Careers
  • Contact
  • Partners

Legal

  • Privacy
  • Terms
  • License
  • Security

© 2025 Monexa. All rights reserved. Market data provided by financial exchanges and may be delayed as specified by financial exchanges or our data providers.